Exposure to high-risk strains of human papillomavirus (HPV) promotes cellular dysplasia of the anal canal epithelium, potentially leading to anal intraepithelial neoplasia (AIN), which is in turn a precursor to invasive squamous cell carcinoma of the anus (SCCA). People with HIV infection who engage in anoreceptive intercourse are at heightened risk for acquiring HPV, AIN, and SCCA. Although intravenous 5-fluorouracil (5-FU) is commonly used for treatment of invasive SCCA, there has been little experience with the use of topical 5-FU as therapy for AIN. We retrospectively reviewed records of the first 11 HIV-positive patients treated with topical 5-FU in our anal dysplasia clinic. Six (55%) patients had clinical improvement with reduction in area of dysplasia seen on high-resolution anoscopy (HRA). Three (27%) patients had improvement in AIN pathologic grade. Eight (73%) patients reported mild-to-moderate perianal irritation, which led six to reduce the frequency of 5-FU application. Further study of topical 5-FU for treatment of HIV-associated AIN is warranted.
Introduction
Exposure to high-risk strains of human papillomavirus (HPV) promotes cellular dysplasia of the anal canal epithelium, leading to anal intraepithelial neoplasia (AIN). Anal intraepithelial neoplasia is pathologically graded I, II, or III in terms of increasingly severe dysplasia. Grade I dysplasia is considered low-grade AIN (LGAIN) and grades II and III are considered high-grade AIN (HGAIN). 1 High-grade AIN is a known precursor to squamous cell carcinoma of the anus (SCCA). 2 Patients with HIV infection who have anoreceptive intercourse are at heightened risk for acquiring HPV, AIN, and SCCA. 3 The anal canal epithelium is embryologically similar to that of the female lower genital tract where a similar progression from HPV acquisition, to cervical intraepithelial neoplasia, to potentially invasive cervical carcinoma can be observed. There is increasing evidence that screening for and treating AIN to prevent SCCA in high-risk groups compares favorably with the similar approach used to prevent progression of cervical dysplasia to cervical carcinoma. 4, 5 5-Fluorouracil (5-FU) is a pyrimidine analog antimetabolite drug. It is used intravenously and as an oral prodrug for treatment of a variety of malignancies including invasive and metastatic carcinomas in both HIV-positive and HIV-negative patients. 6, 7 The use of topical 5-FU to prevent the progression of lower genital tract neoplasia to invasive carcinoma has been studied in both HIV-positive and HIV-negative women. [8] [9] [10] Topical 5-FU is also commonly used to treat actinic keratoses and some nonmelanoma skin cancers. 11 For cutaneous disease 5-FU is applied twice daily. There is, however, no standard frequency for its use when applied to the more sensitive nonkeratinized genital or anal mucosa. Although vaginal application of topical 5-FU is well studied and widely accepted in treatment of lower-genital intraepithelial neoplasia; in the United States, this remains an off-label use of the medication. Patients have applied vaginal 5-FU at frequencies ranging from once weekly to twice daily and have experienced local irritation, inflammation, and ulceration as side effects of the treatment. 12 Currently, there is no consensus on how best to treat AIN. High-grade lesions are monitored, excised, or in select medical centers, treated by infrared coagulation and other destructive modalities. Although these treatments may reduce or eliminate areas of AIN, they can be associated with significant morbidity and may not be an option for patients with significant disease burden such as dysplasia encompassing large areas of the anal canal, especially circumferential disease. Topical medications including 5-FU are also being investigated for treatment of AIN. 13 Herein, we report our initial experience with the use of topical 5-FU for treatment of HIV-associated diffuse AIN.
Methods
Following approval from the Virginia Mason Benaroya Research Institute Institutional Review Board, we retrospectively reviewed medical records including anal colposcopic images of patients who were seen and evaluated in our anal dysplasia clinic between January 1, 2008, and April 1, 2010. We included for data analysis only those patients who were HIV sero-positive, had biopsy-proven AIN, and were prescribed topical 5-FU to treat AIN. We excluded patients who had no follow-up after initial prescription of 5-FU. Twelve patients were initially identified who met inclusion criteria, but 1 patient was excluded because he failed to apply topical 5-FU to the anal mucosa.
We collected patient demographic and behavioral information (age, race, gender, sexual orientation, and sexual practices) from medical records. We recorded details regarding patient HIV status including current highly active antiretroviral therapy (HAART), most recent CD4 count, and HIV viral load. We reviewed clinical notes and anal colposcopic images for detailed descriptions of areas of anal dysplasia before and after topical 5-FU treatment. We evaluated anal cytology and biopsy results before and after treatment. We also assessed changes in 5-FU dosing or frequency during treatment period and any adverse events reported to or observed by the high-resolution anoscopy (HRA) provider during treatment.
All patients underwent HRA before and after treatment with topical 5-FU. High-resolution anoscopy was performed as detailed below, which has been previously described in the literature. 14, 15 Patients were placed in the left lateral decubitus position and a Dacron swab was used to obtain anal cytology. Digital rectal exam was performed to palpate any abnormal areas in the anal mucosa. With the use of a mixture of lubricating jelly and 2% lidocaine, the anoscope was inserted into the anal canal, through which was placed a wooden gauze-wrapped Q-tip soaked in 3% acetic acid solution. The anoscope was then removed and the Q-tip was allowed to remain in place for 1 to 2 minutes, after which the Q-tip was removed and the anoscope reinserted. The anal canal and squamocolumnar junction were visualized using a colposcope. In a manner analogous to cervical colposcopy, areas of anal dysplasia stain acetyl white. When it was desirable to focus biopsies on the worst areas of dysplasia within large areas of acetyl white, Lugol's iodine solution was further used to distinguish areas of dysplasia from normal mucosa. Digital photographs were obtained through the colposcope during HRA.
Anal intraepithelial neoplasia was established by pretreatment anal biopsies and monitored by subsequent biopsies. Anal biopsies were collected during HRA procedures of the one or multiple areas with the most clinically severe dysplasia. These areas of dysplasia were identified by abnormal firmness on digital examination, abnormal staining, or other abnormal appearance on anoscopy such as punctate or mosaic appearance of mucosa, condylomatous changes, proliferative appearance of blood vessels, erosions, or ulcerations. Where multiple biopsies were obtained during the same HRA procedure, we report the highest (most severe) pathologic grade of AIN among the biopsies. Anal cytology was reported as normal, atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL), or high-grade squamous intraepithelial lesion (HSIL).
We instructed patients to apply a pea-sized (approximately 0.25 g) amount of 5% topical 5-FU intra-anally at night before bed, to wash their hands after application, and to wash the anal area in the morning. Patients began with nightly applications but were advised to titrate 5-FU frequency downward if they experienced moderate or severe perianal irritation or pain. At each subsequent clinic visit, the treating provider recorded changes in 5-FU application frequency and the reasons for those changes. With each HRA follow-up examination, the overall area of anal dysplasia (identified by staining and other features as described above) was compared to areas identified and photographed at the time of initial HRA. Clinical improvement was defined as a decrease in this area observed by the HRA provider. Pathologic improvement was defined as decreased grade or absence of AIN on follow-up biopsy or lack of identifiable dysplasia to biopsy.
Results
All 11 participants were male and engaged in anoreceptive intercourse with other men. Ten were Caucasian and one was Hispanic. Patient demographics, HIV status, and clinical data are reported for all patients (Table 1 ). Their median age was 45 years (range, 32 to 67), their median CD4 count was 416 cells/m 3 (range, 35 to 730) and their median HIV viral load was <75 copies/mL (range, <75 to 172,966). Nine (82%) patients were taking HAART concurrent with topical 5-FU. Eight (73%) patients experienced some degree of perianal irritation (defined as pain, irritation, or erythema of the anus, perineum, or posterior scrotum). Seven (64%) patients decreased the frequency of 5-FU application; 6 did so due to perianal irritation and 1 did not indicate a reason. One (9%) patient discontinued 5-FU after only 4 days citing severe anal irritation as the reason he did so, and he declined further treatment. Of the 10 patients who continued topical 5-FU treatment as directed, median treatment duration was 20 weeks (range, 7 to 36). One patient had new anal fissures during the 12th week of treatment, his 5-FU frequency was reduced from nightly to every other night and by week 20, the fissures had healed. One patient had a viral culture-confirmed perianal herpes simplex type II outbreak during his 8th week of 5-FU treatment. 5-Fluorouracil was discontinued and he was treated with acyclovir, which led to rapid resolution of the outbreak; he declined to resume treatment. No other complications were identified during active treatment.
After topical 5-FU treatment, 6 (55%) patients had a decrease in area of anal dysplasia on follow-up HRA. Three (27%) patients had lower grades of AIN on biopsy after treatment. One patient had normal-appearing mucosa on posttreatment HRA, with no identifiable dysplasia and consequently no biopsy was obtained. Pretreatment, this patient had diffuse circumferential condylomatous changes, and biopsy identified AIN I arising within a condyloma. Digital images of this patient obtained during HRA before and after treatment are shown (Figure 1) . The severity of dysplasia on pretreatment and posttreatment anal cytology did not correlate with severity of dysplasia on biopsy in our patients ( Table 1) .
Discussion
There is a long latency period associated with the progression from acquiring HPV to developing invasive SCCA. In the pre-HAART era, most patients with AIDS did not survive long enough to develop conditions with such a prolonged latency as SCCA. With HAART, HIV-infected individuals may now live as long as their non-HIV-infected counterparts. The incidence of SCCA has been reported as ranging between 35 and 70 cases per 100 000 HIV-infected men who have sex with men, approaching the incidence of cervical cancer before widespread Papanicolaou smear screening and compared to an incidence of SCCA of only 0.5 cases per 100 000 in the general population. 5 Although HAART can induce remission of some HIV-associated malignancies, most notably Kaposi's sarcoma, it does not cause regression of AIN. The incidence of invasive SCCA in HIV-infected men continues to rise, more than doubling since the introduction of HAART. 16, 17 The latency period during which HPV induces anal dysplasia and then progresses to anal cancer can also be viewed as an opportunity. Since AIN and, in particular, HGAIN is a known precursor of SCCA, monitoring for and treating anal dysplasia may lead to a reduction in the incidence of SCCA. 3, 4 The data are promising for the use of destructive therapies (ie, infrared coagulation, excision) in a targeted fashion to treat focal HGAIN, but targeted destruction is only an option when areas of AIN are limited. [18] [19] [20] If a medical therapy such as topical 5-FU could be used to minimize the extent of AIN, patients who previously were not candidates for destructive therapies due to diffuse areas of AIN might become candidates for focused or localized destruction.
Further study of topical 5-FU for treatment of AIN is warranted. Four (36%) patients had pathologic improvement after topical 5-FU treatment. However, 2 of those who improved went from AIN III to AIN II and thus still had high-grade dysplasia. The patient with no residual dysplasia initially had AIN I. That leaves one patient whose HGAIN resolved with treatment, going from AIN II to AIN I. Comparison between our biopsy and anal cytology results shows that repeated targeted biopsies remain essential to monitor the progression of AIN once it has been identified, as there was little concordance between the severity of dysplasia on anal cytology and the grade of AIN on biopsy. This is in agreement with previously published results, which have shown a similar inability to use anal cytology to predict high-grade dysplasia. 21 A higher proportion of patients showed clinical improvement, with 6 (55%) patients achieving reductions in the area of dysplasia visualized on HRA. Given our understanding of the pathophysiologic progression from HPV acquisition, to LGAIN, to HGAIN, to SCCA, it is likely that many areas of HGAIN occur within a background of LGAIN. With many patients showing clinical improvement while continuing to have HGAIN on targeted biopsies of the most severe dysplasia, and with the most dramatic clinical response seen in a patient with LGAIN, it seems likely that low-grade dysplasia responds more readily to topical 5-FU than does high-grade dysplasia.
There are inherent limitations to a small retrospective study such as ours, especially in studying treatment of a precursor lesion to a condition with a long latency. Retrospective studies present an inherent risk for bias. Even if a larger prospective study demonstrates effectiveness of topical 5-FU in treating AIN, there is not universal agreement that treatment of AIN will reduce the incidence of SCCA. 22 Ultimately, the ideal outcome to measure is the rate of SCCA. Given the low overall incidence of SCCA and the long latency for it to develop, the number of patients and length of follow-up for such a study would be prohibitive. No prospective controlled study has demonstrated the effectiveness of treating cervical intraepithelial neoplasia in preventing cervical carcinoma, even as screening for and treatment of cervical dysplasia has drastically reduced the incidence of cervical cancer in the Western world. 23 Despite our experience, the ideal dosing of topical 5-FU application remains uncertain. Preliminary results presented by a European group using a fixed application frequency and a larger amount of topical 5-FU in each application showed a much higher rate of more severe side effects than in our patients. 13 Counseling patients about expected perianal irritation and allowing them to titrate frequency allowed patients in our cohort to achieve a well-tolerated application frequency. The resulting variability in final application frequencies also leads to the question of treatment duration. If a tolerable dosing regimen is achieved, should patients continue topical 5-FU indefinitely? The effects of long-term anal 5-FU application remain unknown. Alternatively, if topical 5-FU is stopped after some specified number of applications or after histologic improvement is achieved, will any gains achieved with treatment be durable?
Our results for treatment of HIV-associated AIN with topical 5-FU are encouraging. Based on our initial experience, we believe that further study of topical 5-FU is warranted, as monotherapy either to decrease the severity of dysplasia or to reduce the area of dysplasia and facilitate targeted destruction of residual HGAIN. Only through large, prospective studies will we be able to address issues such as treatment frequency and duration, to quantify subjective side effects such as pain, and to establish the causal relationship between treatment and histologic improvement. Ultimately, we hope future studies will demonstrate that a program of screening for and treatment of anal dysplasia, including with topical 5-FU, can reduce the incidence of invasive SCCA just as similar programs have reduced the incidence of invasive cervical carcinoma.
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